Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study
Highly Positive Clinical Data on Completion of Testing for First Subject Dosed Twice Daily with QRX003 in Open-Label StudyDemonstrated Clinical ...
Yahoo Finance1mon
Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study
Dr. Amy Paller said, “The best kind of treatment ... could be an ideal approach.” Quoin CEO, Dr. Michael Myers, added, “Following our recent announcement of positive interim clinical ...
Morningstar10d
PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers
In addition, Dr. Myers discussed recent FDA clearance for Quoin’s whole-body clinical study, to be led by Dr. Amy Paller at Northwestern University, which will evaluate the safety and efficacy ...
Morningstar12d
Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study
Quoin CEO, Dr. Michael Myers ... which will be conducted by Dr. Amy Paller at Northwestern University. We previously announced FDA clearance to proceed with this study under an open ...
Finanznachrichten1mon
Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study
Dr. Amy Paller said, "The best kind of treatment ... could be an ideal approach." Quoin CEO, Dr. Michael Myers, added, "Following our recent announcement of positive interim clinical data from ...
Stockhouse11d
Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study
Quoin CEO, Dr. Michael Myers ... which will be conducted by Dr. Amy Paller at Northwestern University. We previously announced FDA clearance to proceed with this study under an open Investigational ...